Dark Blue Therapeutics

Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs.

The company applies targeted protein degradation to exploit novel cancer vulnerabilities, with a lead programme targeting the MLLT1/3 proteins implicated in acute myeloid leukaemia.

Its pipeline is built on cancer biology originating from the University of Oxford, matched to molecularly defined patient populations to address unmet clinical need.